WuXi XDC Cayman Inc. (HKG:2268)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
41.70
+0.70 (1.71%)
Jun 6, 2025, 4:08 PM HKT
157.41%
Market Cap 50.15B
Revenue (ttm) 4.31B
Net Income (ttm) 1.14B
Shares Out 1.20B
EPS (ttm) 0.88
PE Ratio 47.21
Forward PE 31.94
Dividend n/a
Ex-Dividend Date n/a
Volume 4,261,566
Average Volume 5,275,263
Open 41.40
Previous Close 41.00
Day's Range 40.20 - 42.10
52-Week Range 14.08 - 49.50
Beta n/a
RSI 58.35
Earnings Date May 21, 2025

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. The company engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It provides international sales contracting, biologics discovery, development, and manufacturing services. The company... [Read more]

Sector Healthcare
Founded 2013
Employees 2,041
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2268
Full Company Profile

Financial Performance

In 2024, WuXi XDC Cayman's revenue was 4.05 billion, an increase of 90.80% compared to the previous year's 2.12 billion. Earnings were 1.07 billion, an increase of 277.24%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.